Mesenchymal Stem Cell: Does it Work in an Experimental Model with Acute Respiratory Distress Syndrome?
- 602 Downloads
We hypothesized that bone marrow-derived mesenchymal stem cells (BM-MSCs) would have a possible role in the treatment of acute respiratory distress syndrome (ARDS). ARDS disease model was developed in Wistar albino male rats by intratracheal instillation of physiological saline solution. Anesthezied and tracheotomized rats (n = 8) with ARDS were pressure-controlled ventilated. Isolated and characterized rat (r-) BM-MSCs were labeled with GFP gene, and introduced in the lungs of the ARDS rat-model. After applying of MSCs, the life span of each rat was recorded. When rats died, their lung tissues were removed for histopathological examination. Also the tissue sections were analyzed for GFP labeled rBM-MSCs and stained for vimentin, CK19, proinflammatory (MPO, IL-1β, IL-6 and MIP-2) and anti-inflammatory [IL-1ra and prostaglandin E2 receptor (EP3)] cytokines. The histopathological signs of rat-model ARDS were similar to the acute phase of ARDS in humans. rBM-MSCs were observed to home in lung paranchyma. Although the infiltration of neutrophils slightly decreased in the interalveolar, peribronchial and perivascular area, a notable improvement was determined in the degree of hemorrhage, edema and hyaline membrane formation in rats treated with rBM-MSCs. Also decreased proinflammatory cytokines levels and increased the intensity of anti-inflammatory cytokines were established. Therefore MSCs could promote alveoar epithelial repair by mediating of cytokines from a proinflammatory to an anti-inflammatory response. As a novel therapeutic approach, mesenchymal stem cell treatment with intratracheal injection could be helpful in the management of critically ill patients with ARDS.
KeywordsAcute respiratory distress syndrome Mesenchymal stem cell Cytokine Inflammation Critically ill
This work was supported by the Cukurova University Research (TF2011BAP20) Fund. The authors thank Kezban Bostaner, Recep Mutlu and Gizem Turaç for their technical assistance. We also express our gratitude to Dr. Gökhan Duruksu for editing of this manuscript.
Conflict of Interest Statement
None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
- 14.Gupta, N., Su, X., Popov, B., Lee, J. W., Serikov, V., & Matthay, M. A. (2007). Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. Journal of Immunology, 179(3), 1855–1863.Google Scholar
- 18.Lee, J. W., Fang, X., Gupta, N., Serikov, V., & Matthay, M. A. (2009). Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proceedings of the National Academy of Sciences, 106(38), 16357–16362.CrossRefGoogle Scholar
- 26.Geiser, T., Atabai, K., Jarreau, P. H., Ware, L. B., Pugin, J., & Matthay, M. A. (2001). Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an il-1beta-dependent mechanism. American Journal of Respiratory and Critical Care Medicine, 163(6), 1384–1388.PubMedGoogle Scholar
- 27.Chimenti, L., Luque, T., Bonsignore, M. R., Ramírez, J., Navajas, D., & Farré, R. (2012). Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. European Respiratory Journal. doi: 10.1183/09031936.00153211.
- 36.Moore, B. B., Ballinger, M. N., White, E. S., et al. (2005). Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. Journal of Immunology, 174(9), 5644–5649.Google Scholar